Drug intelligence / Profile preview

Inactivated SARS-CoV-2 vaccine + measles-mumps-rubella vaccine

Development stage: Unknown
Lead developer: Beijing Institute of Biological Products
Modality: Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous

Overview

A combination of two vaccines: - **Inactivated SARS-CoV-2 vaccine** is a whole-virus, inactivated (killed) preparation of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), developed to induce immunity against COVID-19. It works by exposing the immune system to an inactivated form of the virus, prompting antibody and cellular immune responses without causing disease[1][5]. - **Measles-mumps-rubella (MMR) vaccine** is a live attenuated viral vaccine containing weakened forms of measles, mumps, and rubella viruses. It induces protective immunity by stimulating both humoral and cellular immune responses specific to these viruses[2]. This combination would theoretically provide immunization against COVID-19 as well as measles, mumps, and rubella. There is no evidence that such a fixed-combination product exists or is approved; this entry describes the co-administration or hypothetical combination.

Other names: inactivated SARS-CoV-2 vaccine + MMR

Targets

MV (Measles virus)RBD (SARS-CoV-2 spike receptor-binding domain)E1/E2 (Rubella virus envelope glycoproteins)

Beyond the preview

Go deeper on Inactivated SARS-CoV-2 vaccine + measles-mumps-rubella vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inactivated SARS-CoV-2 vaccine + measles-mumps-rubella vaccine.

Explore the full profile